Treatment for Spinal Muscular Atrophy

    loading  Checking for direct PDF access through Ovid


In a randomized, double-blind, sham-controlled study of infants with spinal muscular atrophy (SMA) type 1, nusinersen treatment led to significant improvement in motor milestones and survival without significant adverse reactions. A safety trial of gene therapy for SMA type 1 demonstrated prolonged ventilator-free survival and improved motor milestones with minimal side effects.

    loading  Loading Related Articles